Is Artelo Biosciences, Inc. (ARTL) a Buy, Sell, or Hold?
Artelo Biosciences, Inc.
NASDAQ:ARTL
$1.15 USD
-$0.01 (-0.86%)
- Volume
- 368.63K
- Average Volume
- 1.72M
- Market Capitalization
- $2.68M
- P/E Ratio
- -0.12
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $50.90
- Year Low
- $0.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.79
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Gregory D. Gorgas |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ARTL |
| CUSIP | 04301G706 |
| CIK | 0001621221 |
| Web | https://www.artelobio.com |
| Phone | 858 925 7049 |
| Currency | USD |
| Employees | 7 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.11 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.79 |
| Quick Ratio | 1.79 |
| Cash Ratio | 1.76 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -10.98 |
| Price / Cash Flow | -0.33 |
| Price / Book | 0.13 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.47 |
| Trailing P/E Ratio | -0.12 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-12.88M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -1602.50% |
| Return on Assets | -107.57% |
Financials Score
| AltmanZ Score | -10.05 |
| Piotroski Score | 3.00 |
| Working Capital | 4.59M |
| Total Assets | 12.52M |
| Ebit | -12.78M |
| Market Cap | 2.52M |
| Total Liabilities | 5.85M |
Poll Results
About Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to ... probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
2026-07-14 08:47:00
Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote
2026-07-13 09:02:00
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building on interim findings from CAReS Phase 2 clinical study which demonstrated improvements in body weight, lean body mass and activity levels SOLANA BEACH, Calif.
2026-07-13 09:02:00
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer
2026-07-01 08:42:00
The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain
2026-06-30 08:57:00
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12
2026-06-29 08:45:00
First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced two presentations of clinical and translational research findings supporting the development of ART26.12, the Company's proprietary selective fatty acid binding protein 5 (FABP5) inhibitor, at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium.
2026-06-10 07:38:00
Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London
2026-05-14 16:05:00
SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the quarter ended March 31, 2026, and outlined upcoming milestones across its portfolio.
Frequently Asked Questions
-
What is the current Artelo Biosciences, Inc. (ARTL) stock price?
-
Artelo Biosciences, Inc.(NASDAQ:ARTL) stock price is $1.15 in the last trading session. During the trading session, ARTL stock reached the peak price of $50.904 while $0.961 was the lowest point it dropped to. The percentage change in ARTL stock occurred in the recent session was --0.86% while the dollar amount for the price change in ARTL stock was -$-0.01.
-
ARTL's industry and sector of operation?
-
The NASDAQ listed ARTL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARTL?
-
Mark E. Spring | Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer
Andrew Yates | Senior Vice President & Chief Scientific Officer
Steven D. Reich | Chief Medical Officer
Jason H. Baybutt | Senior Vice President of Finance
Gregory D. Gorgas | President, Chief Executive Officer, Secretary & Director -
How many employees does ARTL have?
-
Number of ARTL employees currently stands at 7. ARTL operates from 505 Lomas Santa Fe, Solana Beach, CA 92075, US.
-
Link for ARTL official website?
-
Official Website of ARTL is: https://www.artelobio.com
-
How do I contact ARTL?
-
ARTL could be contacted at phone #858 925 7049 and can also be accessed through its website. ARTL operates from 505 Lomas Santa Fe, Solana Beach, CA 92075, US.
-
How many shares of ARTL are traded daily?
-
The average number of ARTL shares traded daily for last 3 months was 1.72M.
-
What is the market cap of ARTL currently?
-
The market value of ARTL currently stands at $2.68M with its latest stock price at $1.15